APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05701306
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
Named Patient Program for Olverembatinib (HQP1351)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Registration Number
- NCT05594758
The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05517616
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05415098
- Locations
- 🇺🇸
Highlands Oncology, Springdale, Arkansas, United States
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05186012
- Locations
- 🇨🇳
Henan Provincial Oncology Hospital, Zhengzhou, Henanan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Shanghai Jiao Tong University school of medicine Ruijin Hospital, Shanghai, China
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05147467
- Locations
- 🇨🇳
The First Affilated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04964518
- Locations
- 🇺🇸
UCLA Medical cetner Division of Hematology, Los Angeles, California, United States
🇺🇸MDACC, Houston, Texas, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04946864
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇺🇸MD Anderson, Houston, Texas, United States
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04942067
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Weil Cornell Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic Hosptials, Cleveland, Ohio, United States
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04893759
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China